TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06706076: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Sponsor: BlossomHill Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 675 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$8,011,080

Rescue Site Savings

+$5,301,450

Unlock Full NCT06706076 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06706076 Rescue Dossier →